The Role of PBMs in Managing High Drug Costs Highlights AJPB Week in Review

Article

Most read articles of the week on The American Journal of Pharmacy Benefits.

Related Videos
Credit: Adobe Stock - Tierney
https://www.youtube.com/watch?v=Q-WCvWaAcC8
Yaruniv-Studio - stock.adobe.com
Technician- © pharmacytimes
Pills on a background of a one hundred American dollar bill | Image credit: Cagkan - stock.adobe.com
Credit: Cagkan - stock.adobe.com
Specialty pharmacy illustration | Image credit: BillionPhotos.com - stock.adobe.com
Biosimilars | Image credit: lexiconimages - stock.adobe.com
Related Content

Artificial Intelligence Is Revolutionizing Controlled Substance Diversion Detection

September 14th 2023

Pharmacy Focus: Psychedelic Pharmacy - Ibogaine Offers Unique Benefits

September 8th 2023

Phase 3 Trial Shows Combined Nivolumab, Ipilimumab Treatment Improved OS in Patients With mNSCLC

September 12th 2023

Pharmacy Focus: Psychedelic Pharmacy - Managing Potential Adverse Effects With Psychedelic Medicines

May 19th 2023

FDA Approves IND for CT7439, a Novel CDK12/13 Inhibitor to Treat Multiple Types of Advanced Solid Tumors

September 11th 2023

Inhibiting PI3K/mTOR, SIRT2 Pathways May Be Effective in Treating Aggressive AML

September 11th 2023

Artificial Intelligence Is Revolutionizing Controlled Substance Diversion Detection

September 14th 2023

Pharmacy Focus: Psychedelic Pharmacy - Ibogaine Offers Unique Benefits

September 8th 2023

Phase 3 Trial Shows Combined Nivolumab, Ipilimumab Treatment Improved OS in Patients With mNSCLC

September 12th 2023

Pharmacy Focus: Psychedelic Pharmacy - Managing Potential Adverse Effects With Psychedelic Medicines

May 19th 2023

FDA Approves IND for CT7439, a Novel CDK12/13 Inhibitor to Treat Multiple Types of Advanced Solid Tumors

September 11th 2023

Inhibiting PI3K/mTOR, SIRT2 Pathways May Be Effective in Treating Aggressive AML

September 11th 2023

Artificial Intelligence Is Revolutionizing Controlled Substance Diversion Detection

September 14th 2023

Pharmacy Focus: Psychedelic Pharmacy - Ibogaine Offers Unique Benefits

September 8th 2023

Phase 3 Trial Shows Combined Nivolumab, Ipilimumab Treatment Improved OS in Patients With mNSCLC

September 12th 2023

Pharmacy Focus: Psychedelic Pharmacy - Managing Potential Adverse Effects With Psychedelic Medicines

May 19th 2023

FDA Approves IND for CT7439, a Novel CDK12/13 Inhibitor to Treat Multiple Types of Advanced Solid Tumors

September 11th 2023

Inhibiting PI3K/mTOR, SIRT2 Pathways May Be Effective in Treating Aggressive AML

September 11th 2023
© 2023 MJH Life Sciences

All rights reserved.